

# Q2 Half-yearly report

January–June 2025

President and CEO Hannu Martola | 7 August 2025





Q2 2025

24.4  
net sales, €m  
(26.1)

-6.6  
net sales change-%  
(3.5)

1.7  
EBITA, €m  
(3.3)

7.0  
EBITA-%  
(12.7)



## Sales declined, yet the company's market position remained solid



Sales declined due to the halt in security CT system installations and unfavourable currency effects

### Industrial sales +4%

- Driven by significant growth in TFT flat panel detectors
- Demand for defence applications intensified

### Medical sales +14%

- Demand for medical CT applications strengthened, particularly in China, where the business after the healthcare reform continued to clear


### Security sales -28%

- The dip in demand was deeper than expected, leading to a sharp decline in EMEIA sales
- The halt in security CT system installations in Europe due to the so-called 100 ml liquid rule weighed on performance, but the restrictions are now lifted
- Market position remained intact

# Net sales by quarter




(EUR 1,000)




**-6.6**  
(YOY change-%)

# Operating margin (EBITA) excluding NRI



# Q2 2025 sales split by regional business units



AMERICAS

NET SALES €m    YOY CHANGE-%

1.5    -5.2


APAC

18.2    8.6

EMEIA

4.7    -39.6

# Q2 2025 sales split by main applications



	NET SALES €m	YOY CHANGE-%
INDUSTRIAL	5.6	4.2
MEDICAL	10.6	13.9
SECURITY	8.2	-28.2



# H1 2025

## 46.6

net sales, €m  
(48.8)

## -4.5

net sales change-%  
(1.7)


## 3.1

EBITA, €m  
(5.6)

## 6.7

EBITA-%  
(11.4)

# H1 2025 sales split by regional business units



AMERICAS

APAC

EMEIA


NET SALES €m    YOY CHANGE-%

2.4    -4.8

34.2    5.5

10.1    -27.5

# H1 2025 sales split by main applications



NET SALES €m    YOY CHANGE-%

INDUSTRIAL	9.3	4.2
MEDICAL	21.4	13.8
SECURITY	15.9	-24.4

# Key figures



	Q2 2025	Q2 2024	H1 2025	H1 2024	FY 2024
Net sales, EUR 1,000	24,372	26,093	46,621	48,799	107,514
Change in net sales, %	-6.6%	3.5%	-4.5%	1.7%	3.6%
EBITA, EUR 1,000	1,702	3,306	3,101	5,570	14,892
EBITA, %	7.0%	12.7%	6.7%	11.4%	13.9%
R&D costs, EUR 1,000	3,146	3,049	5,781	5,560	11,379
R&D costs, % of net sales	12.9%	11.7%	12.4%	11.4%	10.6%
Cash flow from operating activities, EUR 1,000	458	3,911	1,897	6,827	20,133
Investments, EUR 1,000	1,144	352	1,548	1,485	2,218
Return on investment (ROI, 12-month rolling), %	14.7%	13.9%	14.7%	13.9%	17.4%
Earnings per share, EUR	0.07	0.15	0.11	0.26	0.76

## H1 strategy highlights

Maintained strong momentum in flat panel detector sales, up 40% in H1

Rolled out several notable products: X-Panel 43108a, X-Cargo, and X-Panel 2520z

Progressed in ramping-up operations in India

Made an investment in new technology





## DT2030 strategy

We will deliver **smart X-ray detector solutions** that drive customer success through **exceptional usability** to **outgrow the market.**

DT is renewing its strategy for the next five-year period, as the current strategic period will conclude at the end of 2025, and is presenting the strategy details later this year.



## Other events

Advanced its sustainability agenda through focused initiatives

- Increased the use of green energy
- Promoted environmental and work safety awareness
- Conducted DT Heartbeat pulse survey with a stable average score of 3.4/4
- Enhanced Lean Six Sigma capabilities
- Continued to advance children's rights with UNICEF Finland as a member of the Ahlström Collective Impact (ACI) network



# Sales expectation Q3 and H2 2025



## Industrial

to grow  
in Q3



## Medical

to decline  
in Q3



## Security

to decline  
in Q3




Sales in APAC and EMEA to remain stable, and in Americas to decline by double digits in Q3  
YOY total **net sales to decline by a single digit in Q3 and H2 of 2025**

# Business outlook

Detection Technology expects **a single digit year-on-year net sales decline in Q3 and H2 of 2025.**

The geopolitical situation, new U.S. import tariffs, U.S. relations with other countries, China's healthcare reform, and price competition especially in China create uncertainty.



## FINANCIAL TARGETS

MEDIUM TERM  
Annual  
sales growth  
**>10%**

MEDIUM TERM  
Operating  
margin (EBITA)  
**15%**

ANNUAL  
Dividend or  
returned capital  
**30-60%**



# Detection Technology

[www.deetee.com](http://www.deetee.com)